Epcoritamab in Richter Transformation: Insights from a Real-World Case Series
Open Access
- 3 June 2026
- journal article
- Published by American Society of Hematology in Blood Advances
- Vol. 10 (14) , 5070-5073
Abstract
No abstract availableThis publication has 14 references indexed in Scilit:
- Infections after bispecific antibodies in B-cell lymphomasBlood Advances, 2026
- Epcoritamab monotherapy for Richter transformation (EPCORE CLL-1): findings from a single-arm, multicentre, open-label, phase 1b/2 trialThe Lancet Haematology, 2025
- International consensus statement on diagnosis, evaluation, and research of Richter transformation: the ERIC recommendationsBlood, 2025
- Epcoritamab plus GemOx in transplant-ineligible relapsed/refractory DLBCL: results from the EPCORE NHL-2 trialBlood, 2025
- Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2024
- CLL-280 Epcoritamab Induces Deep Responses in Patients With Richter Transformation (RT): Primary Results From the EPCORE CLL-1 TrialClinical Lymphoma Myeloma and Leukemia, 2024
- Allogeneic hematopoietic stem-cell transplantation for patients with Richter transformation: a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMTBone Marrow Transplantation, 2024
- GLOFITAMAB MONOTHERAPY INDUCES DURABLE COMPLETE REMISSIONS AND HAS A MANAGEABLE SAFETY PROFILE IN PATIENTS WITH RICHTER’S TRANSFORMATIONHematological Oncology, 2023
- Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma–type Richter syndromeBlood Advances, 2021
- Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trialsLeukemia, 2020